Reductions of the fat metabolism observed in response to belzutifan treatment (inhibition of CD36-dependent uptake of fatty acids and lipid incorporation) and the triglyceride production mediated by LPCAT1 correlate clinically with a radiographic tumor regression and symptomatic recovery (9). This evidence concerns the gene CD36 and neoplasm.